Cancer drug discovery

WIN for blocking cancer growth

William Tansey and colleagues identified proteins that interact with the cancer drug target WDR5 and are important for cancer cell growth.

Clinical study tests drug that may prevent cancer metastasis

A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

Cancer’s SOS

Stephen Fesik and colleagues are advancing cancer drug discovery with the characterization of small molecules that modulate RAS, an important target for anti-cancer therapies.

STINGing combination for cancer

A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer.

By VUMC News and Communications

Improving therapies for GI tumors

A signaling protein overexpressed in upper gastrointestinal cancers is an attractive therapeutic target.

Kleberg Foundation grant bolsters cancer drug discovery efforts

The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation has awarded a $3 million grant to Vanderbilt-Ingram Cancer Center (VICC) investigators in support of VICC’s drug discovery program. The gift awarded over the next three years from the private, San Antonio, Texas-based foundation will enable VICC researchers to pursue the development of new compounds to block the activity of cancer-causing genes and proteins that had previously been considered “undruggable.”